Search results
Results From The WOW.Com Content Network
Today, the majority of clinical trials evaluating cancer treatments for objective response in solid tumors use RECIST. These criteria were developed and published in February 2000, and subsequently updated in 2009. The criteria are specifically not meant to determine whether patients have improved or not, as these are tumor-centric, not patient ...
PET response criteria in solid tumors (PERCIST) is a set of rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, using positron emission tomography (PET). The criteria were published in May 2009 in the Journal of Nuclear Medicine (JNM). [1]
The immune-related response criteria, first published in 2009, [1] arose out of observations that immuno-oncology drugs would fail in clinical trials that measured responses using the WHO or RECIST Criteria, because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune ...
Solid Converter PDF is document reconstruction software from Solid Documents which converts PDF files to editable formats. Originally released for the Microsoft Windows operating system, a Mac OS X version was released in 2010. The current versions are Solid Converter PDF 9.0 for Windows and Solid PDF to Word for Mac 2.1.
In medicine (oncology and other fields), performance status is an attempt to quantify cancer patients' general well-being and activities of daily life. This measure is used to determine whether they can receive chemotherapy, whether dose adjustment is necessary, and as a measure for the required intensity of palliative care.
The Deauville 5-point scoring system is an internationally accepted and utilized five-point scoring system for the fluorodeoxyglucose (FDG) avidity of a Hodgkin lymphoma or Non-Hodgkin lymphoma tumor mass as seen on FDG positron emission tomography: [1]
The Immunologic Constant of Rejection (ICR), is a notion introduced by biologists to group a shared set of genes expressed in tissue destructive-pathogenic conditions like cancer and infection, along a diverse set of physiological circumstances of tissue damage or organ failure, including autoimmune disease or allograft rejection. [1]
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. The field of cancer immunology studies such topics.